Umut ELBOĞA, Seyhan KARAÇAVUŞ, Ebuzer KALENDER

MEME KANSERİNDE POZİTRON EMİSYON TOMOGRAFİSİ/ BİLGİSAYARLI TOMOGRAFİ (PET/BT) KULLANIMI

Meme kanseri kadınlarda en sık görülen kanser türüdür ve kanserden olan ölümlerde ikinci sıradadır. Yaygın olarak kullanılan görüntüleme metodları mamografi, ultrasonog- rafi, manyetik rezonans (MR), sintimamografi, tek foton emisyon tomografi ve pozitron emisyon tomografisidir (PET). En etkin kullanılan tarama tekniği mamografidir. Fakat 50 yaş altı kadınlarda % 22 oranında yanlış pozitif sonuca sahiptir. Ultrasonografi ve MR zor vakalarda tamamlaycı metodlar olmakla birlikte, memedeki kitlelerin iyi veya kötü huylu olduğunu belirlemek için daha duyarlı yöntemlere ihtiyaç vardır. Meme kanserinin evrelemesinde ve tedaviye cevabı takip etmede PET giderek artan bir şekilde kullanıl- maktadır. Bu derlemede meme kanserinin tanısında ve takibinde PETin faydaları anla- tılmaktadır.

Use of Positron Emission Tomography / Computed Tomography (PET/CT) in Breast Cancer

Breast cancer is the most frequent cancer in women and is the second lethal malignancy. Commonly used imaging modalities include mammography, ultrasonography, magnetic resonance imaging (MRI), scintimammography, single photon emission computed tomography (SPECT) and positron emission tomography (PET). The most effective screening technique at this time is X-ray mammography. However X-ray mammography has a 22% false positive rate in women under 50. Ultrasonography and MRI are complementary methods for the difficult cases but there is still need to more sensitive methods for determining the benign or malignant nature of the breast masses. PET is increasingly used in staging advanced or recurrent breast cancer and in monitoring response to therapy. In this review the benefits of PET in the diagnosis and following of breast cancer are reported.

PDF

___

1. Can N, Kapucu LÖ, Üner A, ve ark. İleri Evre Meme Kanserinin Takibinde 18F- FDG PET/ BTnin Katkısı. UHOD 2008; 1 (18): 9-15.
2. Hortobagyi GN. Developments in chemotheraphy of breast cancer. Cancer 2000; 80:3073-79.
3. Ries LAG, Eisner MP, Kosary CL. SEER Cancer statistics Review, National Cancer Institute, Bethesda, 2004;1975-2001.
4. Wahl R, Cody R, Hutchins G, et al. Positron emission tomography scanning of primary and metastatic breast cancer with radiolabelled glucose analogue 2-deoxy-2(18F)fluoro-D-glucose. N Engl J Med 1991;324(3):200.
5. Avril N, Schelling M, Dose J, et al. Utility of PET in breast cancer. Clin Positron Imag 1999;2:261-271,
6. Czernin J. 18F-FDG PET in breast cancer: A different view of its clinical use. Mol Imag Biol 2002;4:35-45. in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 2008; 49: 367-74.
7. Flanagan F, Dehdasti F, Siegel B. PET in breast cancer. Semin Nucl Med 1998;28:290- 302.
8. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200-9.
9. Anthony Visioni, Julian Kim. Positron Emission Tomography (PET) for benign and malignant disease. Surg Clin North Am. 2011; 91(1): 249266.
10. Hendricks J. The frequency and consequences of false negative mammograms. Eur J Cancer. 2000;36:44.
16. Groheux D, Hindié E, Delord M, et al. Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer. J Natl Cancer Inst 2012;104:18791887.
17. Veronesi U, De Cicco C, Galimberti VE, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007;18:473-478.
18. Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/ computed tomography compared with conventional imaging procedures. J Clin Oncol 2008; 26: 4746-51.
11. Rosenberg RD, Hunt WC, Williamson MR, et al. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology 1998; 209:511-8.
12. Isidoro A , Casado E, Redondo A, et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 2005; 26:2095-2104.
13. Nieweg OE, Kim EE, Wong W, et al. Positron Emission Tomography with Fluorine- 18- Deoxyglucose in the Detection and Staging of Breast Cancer. Cancer, 1993; 71:3920-3925.
14. Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000;18;3495-3502.
15. Peterson LM, Mankoff DA, Lawton T, et al. Quantitative imaging of estrogen receptor expression
19. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Sem Nucl Med 2005;35:84-99.
20. Eubank WB, Mankoff DA, Takasugi J et al. 18 fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001;19:3516-3523.
21. Cho D, Ahn B, Lee S, et al. Assessment of bone metastasis in breast cancer: comparison between F-18 FDG PET-CT and Tc-99m MDP bone scan. J Nucl Med. 2007;48:368.
22. Yap CS, Seltzer MA, Schiepers C, et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physicians perspective. J Nucl Med 2001;42:1334-7.
23. Olafsen T, Kenanova VE, Sundaresan G, et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 2005; 65: 5907-16.
24. Miller KD, Soule SE, Calley C, et al. Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Res Treat. 2005;89(2):187-97.
25. Rajendran JG, Hendrickson KR, Spence AM, et al. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging 2006;33:44-53.
26. Contractor K, Challapalli A, Tomasi G, et al. Imaging of cellular proliferation in liver metastasis by [18F] fluorothymidine positron emission tomography: effect of therapy. Phys Med Biol. 2012; 7;57(11):3419-33.
27. Yagle KJ, Eary JF, Tait JF, et al. Evaluation of 18F- annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 2005; 46: 658-66.